

Current Report No 6/2022

Signing a commercial agreement to sell Genomtec® ID.

The Management Board of Genomtec S.A. ("Issuer", "Company") announces that today, i.e. 29 April 2022, it signed an agreement with Atropos Ltd., a distributor of laboratory reagents and in vitro diagnostic products based in Greece ("Contractor") for the supply of its flagship product Genomtec® ID ("Agreement"). Under the Agreement, once the Product meets certain conditions, including receipt of a CE mark, the Contractor agreed to place a minimum order for both the analyzer and the respiratory panel infection reaction card ("Product") with a total value of 350 000 EUR in the period of 3 years. The Contractor will have the right of exclusive distribution on the territory of Greece. The Contracting Party is a specialist distributor of molecular biology solutions with an established position on the market.

Pursuant to the Agreement, upon the delivery of the aforementioned order, the Contracting Party may increase the volume of orders beyond the minimum quantity of Products. The remaining provisions of the Agreement do not differ from typical conditions for this type of transactions.

The Management Board of the Company considered the conclusion of the Agreement to be confidential information, because the Contractor declared that in the case of release of the Product to the market and satisfactory performance of the device, it will be ready to place further orders of greater volume, and therefore there are premises that the implementation of the above-mentioned Agreement may have a significant impact on the future revenue situation of the Issuer, as well as on the popularization of the technology and the Company's Product. Therefore, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Article 17.1 MAR.